How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

  • Question on Consultation

    There is a requirement for relevant health bodies to comply with the recommendations in this evaluation within 3 months of the date final guidance is published by NICE (see section 4.1). We are aware there may be system challenges that mean an extension to this normal period may be appropriate because tirzepatide cannot be appropriately administered until:
    • training is in place
    • certain health service infrastructure requirements including goods, materials or other facilities are in place
    • other appropriate health services resources, including staff, are in place. These challenges may include:
    • commissioning arrangements for weight management services
    • how tirzepatide will fit into the current treatment pathway for weight management
    • the provision of counselling, psychological support and concomitant behavioural, dietary and physical activity advice
    • titration of tirzepatide and how a stopping rule based on treatment response at 6 months would be implemented
    • capacity in the system.

  • Question on Consultation

    Please specify any potential challenges with implementing these recommendations and the associated reasons.

  • Question on Consultation

    Please also provide any ways to overcome these potential challenges, any estimate of the time period within which the recommendation can be complied with, and any approaches to phase in funding to manage access to tirzepatide during any potential extended funding variation period.
The content on this page is not current guidance and is only for the purposes of the consultation process.

Tirzepatide for managing overweight and obesity

Closed for comments This consultation ended on at   Request commenting lead permission

4 Implementation

4.1

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care boards, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 3 months of its date of final guidance publication. There may be system challenges that mean an extension to this normal period may be appropriate (see section 3.30 and the request for consultation comments at the start of this draft guidance). If a funding variation request is submitted and accepted by NICE, a consultation with stakeholders will be undertaken on the proposals.

4.2

The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal guidance recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the final draft guidance.

4.3

When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has overweight or obesity and the healthcare professional responsible for their care thinks that tirzepatide is the right treatment, it should be available for use, in line with NICE's recommendations.